On-Demand Webinars for Biotherapeutics Sample Quality Control
Explore the latest advancements in IVT mRNA biotherapeutics quality control (QC) with our comprehensive webinar series. Each session delves into critical aspects of QC analysis and best practices for ensuring the integrity and efficacy of mRNA-based therapeutics.
Join us to learn how Agilent advanced analytical solutions and automated systems can optimize your workflows from early-stage development to final product release.
Watch this insightful session where experts from the BASE mRNA facility at The University of Queensland will present a validated, end-to-end protocol for producing high-quality IVT mRNA suitable for preclinical research. This protocol covers every step—from sequence design and DNA template preparation to mRNA synthesis, LNP formulation, and transfection—supported by robust quality control methods.
What you'll learn:
Measuring critical quality attributes (CQAs) like identity, purity, quality, and quantity is required for the development and production of IVT mRNA modalities, as outlined for example in USP guidelines. This webinar discusses how analytical solutions from Agilent help optimize IVT mRNA workflows from early-stage drug development to final product release and how our systems deliver reliable results.
Ensuring consistent quality throughout IVT mRNA workflows requires reliable and robust sample analysis. This webinar explores the use of Agilent automated electrophoresis systems during IVT mRNA biotherapeutics development, emphasizing quality control and integrity analysis. It also introduces Biofoundry-in-a-Box, a novel technology for rapid RNA manufacturing developed by Centillion.
Producing effective IVT mRNA-based vaccines was crucial in combating COVID-19. This webinar highlights how Agilent Fragment Analyzer systems enhance sample quality assessment for these vaccines. It outlines recommended quality control steps and how the Fragment Analyzer system supports high-precision nucleic acid size and integrity analysis. Additionally, Pfizer’s mRNA manufacturing process and their evaluation of the Fragment Analyzer are discussed.
Assessing nucleic acid integrity, purity, and quantity during critical stages of RNA- and DNA-based vaccine production delivers accurate and reliable sample quality data. In this webinar, Agilent Product Manager Kyle Luttgeharm walks through the in-process sample quality control checks and final vaccine product testing performed on the Agilent Fragment Analyzer systems.
For Research Use Only. Not for use in diagnostic procedures. PR7001-3619